684 related articles for article (PubMed ID: 33274002)
1. Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention.
Cunha-Oliveira T; Montezinho L; Mendes C; Firuzi O; Saso L; Oliveira PJ; Silva FSG
Oxid Med Cell Longev; 2020; 2020():5021694. PubMed ID: 33274002
[TBL] [Abstract][Full Text] [Related]
2. Oxidative Stress as a Therapeutic Target in Amyotrophic Lateral Sclerosis: Opportunities and Limitations.
Park HR; Yang EJ
Diagnostics (Basel); 2021 Aug; 11(9):. PubMed ID: 34573888
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target.
Barber SC; Shaw PJ
Free Radic Biol Med; 2010 Mar; 48(5):629-41. PubMed ID: 19969067
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3β/Nrf2/GCLC pathways.
Zhang C; Yang Y; Liang W; Wang T; Wang S; Wang X; Wang Y; Jiang H; Feng H
Brain Res Bull; 2019 Mar; 146():287-301. PubMed ID: 30690059
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis.
Miquel E; Cassina A; Martínez-Palma L; Souza JM; Bolatto C; Rodríguez-Bottero S; Logan A; Smith RA; Murphy MP; Barbeito L; Radi R; Cassina P
Free Radic Biol Med; 2014 May; 70():204-13. PubMed ID: 24582549
[TBL] [Abstract][Full Text] [Related]
6. Secondary Metabolites with Antioxidant Activities for the Putative Treatment of Amyotrophic Lateral Sclerosis (ALS): "Experimental Evidences".
Silva JM; Nobre MSC; Albino SL; Lócio LL; Nascimento APS; Scotti L; Scotti MT; Oshiro-Junior JA; Lima MCA; Mendonça-Junior FJB; Moura RO
Oxid Med Cell Longev; 2020; 2020():5642029. PubMed ID: 33299526
[TBL] [Abstract][Full Text] [Related]
7. Edaravone May Prevent Ferroptosis in ALS.
Spasić S; Nikolić-Kokić A; Miletić S; Oreščanin-Dušić Z; Spasić MB; Blagojević D; Stević Z
Curr Drug Targets; 2020; 21(8):776-780. PubMed ID: 32077821
[TBL] [Abstract][Full Text] [Related]
8. Astrocytes Pathology in ALS: A Potential Therapeutic Target?
Johann S
Curr Pharm Des; 2017; 23(33):5022-5036. PubMed ID: 28619000
[TBL] [Abstract][Full Text] [Related]
9. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
[TBL] [Abstract][Full Text] [Related]
10. γ-Oryzanol mitigates oxidative stress and prevents mutant SOD1-Related neurotoxicity in Drosophila and cell models of amyotrophic lateral sclerosis.
Zhang C; Liang W; Wang H; Yang Y; Wang T; Wang S; Wang X; Wang Y; Feng H
Neuropharmacology; 2019 Dec; 160():107777. PubMed ID: 31521619
[TBL] [Abstract][Full Text] [Related]
11. α-Lipoic acid attenuates oxidative stress and neurotoxicity via the ERK/Akt-dependent pathway in the mutant hSOD1 related Drosophila model and the NSC34 cell line of amyotrophic lateral sclerosis.
Wang T; Cheng J; Wang S; Wang X; Jiang H; Yang Y; Wang Y; Zhang C; Liang W; Feng H
Brain Res Bull; 2018 Jun; 140():299-310. PubMed ID: 29842900
[TBL] [Abstract][Full Text] [Related]
12. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity.
Birger A; Ben-Dor I; Ottolenghi M; Turetsky T; Gil Y; Sweetat S; Perez L; Belzer V; Casden N; Steiner D; Izrael M; Galun E; Feldman E; Behar O; Reubinoff B
EBioMedicine; 2019 Dec; 50():274-289. PubMed ID: 31787569
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.
Pandya RS; Zhu H; Li W; Bowser R; Friedlander RM; Wang X
Cell Mol Life Sci; 2013 Dec; 70(24):4729-45. PubMed ID: 23864030
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target.
Barber SC; Mead RJ; Shaw PJ
Biochim Biophys Acta; 2006; 1762(11-12):1051-67. PubMed ID: 16713195
[TBL] [Abstract][Full Text] [Related]
15. An in vitro screening cascade to identify neuroprotective antioxidants in ALS.
Barber SC; Higginbottom A; Mead RJ; Barber S; Shaw PJ
Free Radic Biol Med; 2009 Apr; 46(8):1127-38. PubMed ID: 19439221
[TBL] [Abstract][Full Text] [Related]
16. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK
Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
[TBL] [Abstract][Full Text] [Related]
17. Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategies.
Wei Y; Zhong S; Yang H; Wang X; Lv B; Bian Y; Pei Y; Xu C; Zhao Q; Wu Y; Luo D; Wang F; Sun H; Chen Y
Eur J Med Chem; 2024 Jun; 272():116496. PubMed ID: 38759454
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis.
Joshi AU; Saw NL; Vogel H; Cunnigham AD; Shamloo M; Mochly-Rosen D
EMBO Mol Med; 2018 Mar; 10(3):. PubMed ID: 29335339
[TBL] [Abstract][Full Text] [Related]
19. The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis.
Fukunaga K; Shinoda Y; Tagashira H
J Pharmacol Sci; 2015 Jan; 127(1):36-41. PubMed ID: 25704016
[TBL] [Abstract][Full Text] [Related]
20. Mitochondria: A Promising Convergent Target for the Treatment of Amyotrophic Lateral Sclerosis.
Cunha-Oliveira T; Montezinho L; Simões RF; Carvalho M; Ferreiro E; Silva FSG
Cells; 2024 Jan; 13(3):. PubMed ID: 38334639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
